πŸ‡ΊπŸ‡Έ FDA
Patent

US 10125134

KRas G12C inhibitors

granted A61PA61P35/00A61P35/02

Quick answer

US patent 10125134 (KRas G12C inhibitors) held by Mirati Therapeutics, Inc. expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00